Mar
2022
Read more in Clinical Lab Manager on how a plasma-based biomarker discovery platform for non-small cell lung cancer was developed using Seer’s unbiased proteogenomic approach to map protein variants arising from a single gene.
Mar
2022
Published results highlight simultaneous superior performance across depth, precision, and throughput versus conventional plasma proteomics workflows.
Mar
2022
Seer CEO Omid Farohkzad was profiled in the San Francisco Business Times. Read more on his unique career path, what inspires him to continue making an impact in life sciences, and his vision of proteomics for the future of healthcare.
Jan
2022
Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies.
Jan
2022
Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program.
Nov
2021
Researchers from the Oregon Health & Science University, the Broad Institute, Sanford Burnham Prebys Medical Discovery Institute, and proteomics software company Protein Metrics presented data and their experience using Seer’s Proteograph technology. (Premium content, sign in may be required.)
Nov
2021
Seer Welcomes Rachel Haurwitz, Ph.D. to Board of Directors
Oct
2021
Seer CEO Omid Farokhzad shares his perspective on how multidisciplinary approaches, including proteomics and genomics, will greatly expand our knowledge of biology and human health as part of Genetic Engineering & Biotechnology News’ 40th anniversary issue.
Oct
2021
This article in BioCentury explains how ‘omics technologies can improve the runway to drug approvals across diverse disease areas. For mass-spectrometry-based proteomic and metabolomic measurements the ability to capture a wider range of biological complexity is a more direct reflection of a patient’s state of health. (Subscription required)
Jul
2021
Dr. Omid Farokhzad, Chair, CEO and Founder of Seer, discusses how Seer’s cutting edge work with protein and proteomics is removing technological barriers and providing scientists with better tools to make breakthroughs than ever before. Watch the video here
Jul
2021
BioReport Podcast: CEO Omid Farokhzad explains why, although great progress has been made in understanding the human genome, the human proteome remains relatively unexplored.
Jun
2021
Motley Fool: interview with CEO Omid Farokhzad on the future of proteomics.
May
2021
Benzinga: interview with CEO Omid Farokhzad on the importance of proteomics
Mar
2021
Seer signs agreement with Sciex: Seer and SCIEX have signed a commercial agreement to provide end to end unbiased proteomics solutions.
Feb
2021
Seer adds board members: Seer appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors
Jan
2021
Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
Jan
2021
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics
Dec
2020
Seer announced the pricing of its initial public offering of 9,210,527 shares of Class A common stock.
Sep
2020
Seer Appoints Catherine Friedman to its Board of Directors
Sep
2020
Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing
Jul
2020
Seers Announces Publication in Nature Communications Demonstrating Performance, Scalability and Utility of its Platform Technology for Deep, Unbiased Proteomics.
Jun
2021
Seer’s proprietary engineered nanoparticles. Each nanoparticle consists of a magnetic core and a surface with unique physicochemical properties.
Jun
2021
Proteins bind to Seer’s proprietary engineered nanoparticles first by concentration, and then by affinity displacement to form a protein corona.
Jun
2021
Seer’s Proteograph Product Suite is designed to enable unbiased, deep and rapid proteomics at scale.
May
2021
Reverse high resolution Seer logo in white for digital use.